United-Guardian, Inc. is a manufacturer of hydrogels and pharmaceutical products. The company formulates and produces hydrogels that provide smoothness, lubrication, sensory enhancement, moisturization, and texture. Its product portfolio includes the LUBRAJEL hydrogel line, used for personal care products and as lubricants for medical devices such as catheters and endoscopes, and the NATRAJEL hydrogel technologies line, formulated for the sexual wellbeing market. The company also manufactures pharmaceutical products, including CLORPACTIN WCS-90, a topical antimicrobial disinfectant, and RENACIDIN Irrigation Solution, an FDA-approved prescription drug used to prevent and dissolve calcifications in urethral catheters. United-Guardian serves customers in the personal care, medical device, and pharmaceutical sectors, offering customized solutions for various hydrogel applications.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Specialty Chemicals Homepage u-g.com
Sector Basic Materials IR page u-g.com/subscribe-to-investor-mailing-list
Tags
hydrogels, personal care ingredients, medical device lubricants, topical antimicrobials, pharmaceutical formulations, sexual wellbeing products, catheter care, LUBRAJEL, NATRAJEL, CLORPACTIN WCS-90, RENACIDIN Irrigation Solution
Press page u-g.com/press-releases

Metrics

Valuation  
Market cap $ 32.895M
Market cap (USD) $ 32.895M
P/E 10.53
PEG —
P/BV 2.94
P/S 2.64
P/OCF 10.93
P/FCF 11.18
Dividend yield 16.8%
Turnover / mcap —
Returns  
ROE 18.2%
ROI 18.7%
ROIC 15.9%
Profit margin 20.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -6.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score 5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 10.545M 12.182M 10.885M 12.699M 13.93M 10.986M 13.599M 13.769M 12.968M 10.777M 14.006M 13.45M 15.417M 13.826M 14.339M 13.723M 13.277M 12.292M 11.889M 11.208M
Net profit 2.106M 3.251M 2.581M 2.57M 4.659M 3.305M 4.762M 4.352M 3.844M 2.581M 4.607M 4.05M 5.903M 4.831M 4.717M 3.8M 3.879M 3.163M 3.544M 2.737M
Free cash flow 1.908M 3.033M 2.979M 2.45M 5.197M 3.551M 4.362M 4.875M 3.954M 2.124M 5.137M 4.426M 5.517M 5.128M 4.162M 3.639M 4.182M 3.235M 3.855M 2.126M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 6.16 9.56 7.2 10.44 16.44 14.37 19.65 18.34 18.5 15.5 19.15 19.83 28.18 — 14.75 10.75 10.46 9.9 13.11 —
Price performance 12m -0.36 0.33 -0.31 -0.37 0.14 -0.27 0.07 -0.01 0.19 -0.19 -0.03 -0.3 — — 0.37 0.03 0.06 -0.25 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.6M 1.91M 1.67M 2.1M 1.39M 1.81M 1.43M 1.57M 1.43M 1.59M
↳ YoY growth +71.0% +19.2% -12.2% +25.5% -33.9% +30.7% -21.3% +9.8% -8.8% +11.1%
↳ 5y CAGR -0.7% +13.4% -1.4% +5.7% +8.2% +2.6% -5.6% -1.3% -7.4% +2.7%
Cash and deposits (USD) 424,301 724,721 550,135 1.05M 591,444 531,213 830,452 8.24M 1.88M 1.25M
Cash flow detail
Operating cash flow (USD) 2.29M 3.99M 4.95M 4.48M 3.59M 5.31M 2.53M 3.14M 3.47M 1.97M
Purchases of property, plant and equipment (USD) -166,689 -38,149 -74,993 -113,769 -43,395 -116,375 -75,179 -165,716 -433,077 -58,995
Change in receivables (cash effect) (USD) -671,532 -311,695 237,173 -430,127 717,874 -431,883 385,959 -135,872 140,714 -161,261
Change in inventories (cash effect) (USD) 37,829 -84,710 -141,628 249,874 -198,496 4,984 -290,223 465,506 -214,281 -54,976
Change in payables (cash effect) (USD) -13,995 271,464 -167,488 -115,412 -39,585 379,094 -380,479 104,034 290,554 55,788
Dividends paid (cash effect) (USD) -3.44M -6.51M -4.82M -5.05M -3.58M -5.19M -3.12M -459,387 -2.76M -2.77M
Income taxes paid (cash effect) (USD) -1.05M -1.6M -1.15M -1.1M -1.03M -1.1M -1.13M -600,000 -1.05M -300,780
Operating cash flow before change in receivables (USD) 2.96M 4.3M 4.71M 4.91M 2.88M 5.75M 2.14M 3.28M 3.33M 2.13M
Free cash flow (OCF - PPE - intangibles) (USD) 2.12M 3.95M 4.88M 4.36M 3.55M 5.2M 2.45M 2.98M 3.03M 1.91M
Income detail
Research and development expense (USD) 651,828 646,079 399,517 397,391 451,208 478,642 490,770 463,992 456,779 463,644
↳ 5y CAGR +0.5% -1.4% -11.0% -11.5% -7.0% -6.0% -5.4% +3.0% +2.8% +0.5%
Total comprehensive income (USD) 2.68M 4.1M 4.35M — — — — — — —
Comprehensive income to owners (USD) 2.68M 4.1M 4.35M — — — — — — —
Provision for credit losses (USD) 8,289 4,277 -4,325 4,283 -7,161 6,235 -189 -3,391 -2,330 2,827
Credit cost ratio (credit losses / average receivables) (%) 0.7% 0.2% 0.2% 0.2% 0.4% 0.4% 0.0% 0.2% 0.2% 0.2%
Reported Mar 23, 2017 Mar 22, 2018 Mar 21, 2019 Mar 26, 2020 Mar 22, 2021 Mar 23, 2022 Mar 23, 2023 Mar 22, 2024 Mar 21, 2025 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

HAUPPAUGE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and first nine months of 2026. Third quarter net sales increased by 54% from $2,264,261 in 2025 to $3,494,780 in 2026, with net income increasing 247% from $268,441 ($0.06 per share) to $930,912 ($0.20 per share). Net sales for the nine-month period ended September 30th increased by 25% from $7,583,613 in 2025 to $9,475,269 in 2026, and net income increased by 70% from $1,456,162 ($0.32 per share) to $2,478,393 ($0.54 per share).

Donna Vigilante, President of United-Guardian, stated, “I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin®, our most important pharmaceutical product. The increase was partly attributable to the expanded formulary coverage we achieved earlier this year.

UNITED-GUARDIAN REPORTS SECOND QUARTER RESULTS Bull 3 Bear 0 Results

UNITED-GUARDIAN REPORTS

SECOND QUARTER RESULTS

Hauppauge, NY, August 7, 2026 – United-Guardian, Inc. (NASDAQ:UG) announced today the financial

results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from

$2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share)

to $728,579 ($0.16 per share). Net sales for the six-month period ended June 30

th

increased by 12% from

$5,319,352 in 2025 to $5,980,489 in 2026, and net income increased by 30% from $1,187,721 ($0.26 per

share) to $1,547,481 ($0.34 per share).

Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that sales and earnings

increased in both the second quarter and first half of 2026. Sales of our cosmetic ingredients and

pharmaceutical products increased during both periods compared with the same periods in 2025. Cosmetic

ingredient sales increased by 44% in the second quarter and 34% in the first half of 2026 compared with

the same periods in 2025. The growth in cosmetic ingredient sales was primarily attributable to increased

purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. ASI had experienced

higher-than-normal inventory levels in 2025, which have since been reduced, resulting in the resumption

of regular purchasing levels in the first half of 2026. Pharmaceutical sales increased by 1% in the second

quarter and 11% in the first half of 2026 compared with the same periods in 2025, with Renacidin

®

, our

most important pharmaceutical product, serving as the primary driver of growth.”

“As we move through 2026, we remain focused on our growth plan, which includes expanding promotional

efforts and increasing market awareness for Renacidin, particularly among physicians and care providers;

increasing awareness of our “natural” products; and growing our medical lubricant business.”

UNITED-GUARDIAN DECLARES CASH DIVIDEND Bull 3 Bear 0 Capital return

UNITED-GUARDIAN DECLARES

CASH DIVIDEND

Hauppauge, NY, July 16, 2026 – United-Guardian, Inc. (NASDAQ:UG) announced today that the company's

Board of Directors, at its meeting on July 14, 2026, declared a cash dividend of $0.30 per share, to be paid

on August 4, 2026, to all stockholders of record as of the close of business on July 28, 2026. This will be

the 31

st

consecutive year the company has paid a dividend.

Donna Vigilante, President of United-Guardian, stated, “The Board of Directors has approved a cash

dividend of $0.30 per share for our stockholders, representing a 20% increase over the dividend paid this

past February. In determining the dividend, the Board considered several factors, including the company’s

financial performance, anticipated future expenses, and ongoing business initiatives. The decision to

increase the dividend reflects the Board’s assessment of these factors and its continued confidence in the

company’s direction. As we continue to pursue our growth plan and aim to increase revenue across our

market segments, we hope to provide greater dividends to our shareholders in the future.”

Prompts

United-Guardian, Inc. (ticker UG), listed in United States.

ETFs Holding United-Guardian, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 1,437 $ 12.401K Nov 12, 2026
DFAS 0.00% 18,788 $ 162.14K Nov 12, 2026
DCOR 0.00% 2,769 $ 23.896K Nov 12, 2026
DFAC 0.00% 4,887 $ 42.175K Nov 12, 2026
DXUV 0.00% 83 $ 716.29 Nov 12, 2026